Evidence map›Paper›PMID 40879062›Full record

ArticleCancer medicine2025

Proto-Oncogene HRAS Transcript Level and Overall Survival in Stages II and III Colorectal Cancer.

Donghyun Kim, Saima Sharif, Juan Antonio Raygoza Garay, Avanish S Bhakta, Patrick M Boland, Michael J Cavnar, Michelle L Churchman, Hassan Hatoum, Lyen C Huang, Joseph Kim and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Donghyun KimDivision of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA.ORCID https://orcid.org/0009-0005-6998-302X
Saima SharifDivision of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, Iowa, USA.
Juan Antonio Raygoza GarayHolden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa, USA.
Avanish S BhaktaDepartment of Surgery, University of Kentucky, Lexington, Kentucky, USA.
Patrick M BolandDepartment of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.ORCID https://orcid.org/0000-0002-4213-8847
Michael J CavnarDepartment of Surgery, University of Kentucky, Lexington, Kentucky, USA.
Michelle L ChurchmanDepartment of Clinical & Life Sciences, Aster Insights, Hudson, Florida, USA.
Hassan HatoumSection of Hematology-Oncology, Department of Internal Medicine, University of Oklahoma Health Sciences, Oklahoma City, Oklahoma, USA.
Lyen C HuangDivision of Surgical Oncology, Department of Surgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.ORCID https://orcid.org/0000-0002-8605-2631
Joseph KimDepartment of Surgery, University of Kentucky, Lexington, Kentucky, USA.
Richard KimDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, Florida, USA.
Robert W LentzDivision of Medical Oncology, Department of Medicine, University of Colorado, Aurora, Colorado, USA.
Sarbajit MukherjeeDivision of Medical Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Mary T O'DonnellDepartment of General Surgery, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Benjamin QuarteyDepartment of General Surgery, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Matthew J ReilleyDivision of Hematology/Oncology, Department of Medicine, University of Virginia Comprehensive Cancer Center, Charlottesville, Virginia, USA.
Robert J RounbehlerDepartment of Clinical & Life Sciences, Aster Insights, Hudson, Florida, USA.
Bodour SalhiaDepartment of Translational Genomics, University of Southern California, Los Angeles, California, USA.
Bryan P SchneiderDivision of Hematology/Oncology, Department of Medicine, Indiana University, Indianapolis, Indiana, USA.
Carlos H ChanDivision of Surgical Oncology and Endocrine Surgery, Department of Surgery, University of Iowa, Iowa City, Iowa, USA.

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers · 2013 to 2026
$38.3M
NCI NIH HHS P30 CA177558
6 · The paper itself

Abstract

backgroundMutational landscape is prognostic in colorectal cancer (CRC). Rat sarcoma (RAS) oncogenes, such as KRAS and NRAS, with driver mutations, portend poor survival outcomes, whereas pathologic mutations in HRAS are extremely rare, and their prognostic value remains uncertain.

methodsThis retrospective study analyzed the Oncology Research Information Exchange Network (ORIEN) alliance tumor RNA-Seq data in Stages II and III CRC to investigate the association between RAS gene expression and survival outcomes.

resultsHigh transcript levels of HRAS were associated with superior overall survival (OS). The high HRAS-associated OS benefit was most pronounced in patients with right-sided primary expressing low KRAS transcript levels in the absence of pathologic KRAS mutations.

conclusionsContrary to the notion that RAS family genes are proto-oncogenic, this study demonstrates that high HRAS transcript levels are associated with superior OS in Stages II and III CRC. The potential of HRAS as a prognostic biomarker should be explored further.

Indexed as

Biomarkers, TumorColorectal NeoplasmsProto-Oncogene Proteins p21(ras)AgedFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMutationNeoplasm StagingPrognosisProto-Oncogene MasRetrospective StudiesBiomarkers, TumorHRAS protein, humanKRAS protein, humanMAS1 protein, humanProto-Oncogene MasProto-Oncogene Proteins p21(ras)biomarkerscolorectal cancergene expression regulationsurvival

Identifiers

PMID40879062
PMCPMC12311480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.